Astra cannot breathe easy despite first triplet approval
Astrazeneca hopes that its new COPD triplet can gain share from Glaxosmithkline’s rival, but it is not planning a price war.
Rich recognition finally arrives for Array
Pfizer launches an $11.4bn bid for the prolific originator of small molecules, and predicts blockbuster sales in colorectal cancer to help justify the price.
Questions surround Bone Therapeutics’ spine data
The company needed a hit in its spine trial, and it claims to have got one.
Why investors should question Savara's excuse
With the company’s Molgradex failing to beat standard of care in a rare lung disorder, the premise behind this project looks questionable.
Achieve goes up in smoke
Achieve Life Sciences gets a reality check despite largely positive smoking cessation data.
Cymabay can’t buck the Nash disappointment trend
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
ADA 2019 – a good start for Beta Bionics
The iLet system showed decent blood sugar control in its first trial, but the highly automated system is far from proven.
Vertex’s second transformation: Duchenne time
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
Rewalk Robotics suits up
Europe and the US approvals of the ReStore device have arrived within a week; now the company must deliver commercially.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.